Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18160154 | 0.86 | PRMT6 (0.41) | PRMT6THRBTP53NPC1RAB9A | |
| SCHEMBL23665620 | 0.79 | PRMT6 (0.58) | PRMT6THRBTP53NPC1RAB9A | |
| SCHEMBL15330274 | 0.79 | ALDH1A1 (0.36) | TP53NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL1584459 | 0.78 | — | — | |
| SCHEMBL8645292 | 0.75 | KDM4E (0.37) | L3MBTL1ALDH1A1KDM4EGAADAO | |
| SCHEMBL2557730 | 0.75 | MMP8 (0.45) | RAB9ASMN1; SMN2KMT2AALDH1A1HPGD | |
| SCHEMBL28029259 | 0.75 | PRMT6 (0.41) | PRMT6THRBTP53NPC1RAB9A | |
| SCHEMBL147077 | 0.73 | — | — | |
| SCHEMBL5264376 | 0.72 | PRMT6 (0.63) | PRMT6THRBTP53NPC1RAB9A | |
| SCHEMBL16414421 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848617-B1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-01-12 | — | — | EP | disclosed |
| CN-103387583-B | Diaryl simultaneously [a, g] quinolizine class compound, its preparation method, pharmaceutical composition and its application | 中国科学院上海药物研究所 | 2018-04-13 | — | — | CN | disclosed |
| US-9751882-B2 | Diaryl[A, G]quinolizidine compound, preparation method therefor, pharmaceutical composition, and uses thereof | KINGSOUND & PARTNER (CN) | 2017-09-05 | — | — | US | disclosed |
| EP-1891067-B1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150141419-A1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-21 | — | — | US | disclosed |
| EP-2848617-A1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-03-18 | — | — | EP | disclosed |
| CN-103387583-A | Diaryl [a, g] quinolizidine compound, preparation method thereof, pharmaceutical composition, and uses thereof | SHANGHAI INST MATERIA MEDICA | 2013-11-13 | — | — | CN | disclosed |
| US-8580811-B2 | Androgen receptor modulator methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2012-06-28 | — | — | US | disclosed |
| US-8193357-B2 | Androgen receptor modulator compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090264455-A9 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090105234-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090030027-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1891067-A2 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006138347-A2 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2006-12-28 | — | — | WO | disclosed |
| US-5808101-A | 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents | ALLERGAN (US) | 1998-09-15 | — | — | US | disclosed |
| US-5710288-A | 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents | ALLERGAN (US) | 1998-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141419-A1 | DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | HTR5A, HTR1F, QDPR | PRMT6 4475/4885THRB 1572/4885TP53 3950/4885 |
| US-20090105234-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | PRMT6 4284/4885THRB 1132/4885TP53 4507/4885 |
| US-20090030027-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | PRMT6 1239/4885THRB 146/4885TP53 1401/4885 |
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | PRMT6 1239/4885THRB 146/4885TP53 1401/4885 |
| US-20090264455-A9 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | PRMT6 1239/4885THRB 146/4885TP53 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.